The latest price target for Rocket Pharmaceuticals (NASDAQ:RCKT) was reported by Scotiabank on March 3, 2025. The analyst firm set a price target for $52.00 expecting RCKT to rise to within 12 months (a possible 481.01% upside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for Rocket Pharmaceuticals (NASDAQ:RCKT) was provided by Scotiabank, and Rocket Pharmaceuticals maintained their sector outperform rating.

There is no last upgrade for Rocket Pharmaceuticals

There is no last downgrade for Rocket Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rocket Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rocket Pharmaceuticals was filed on March 3, 2025 so you should expect the next rating to be made available sometime around March 3, 2026.

While ratings are subjective and will change, the latest Rocket Pharmaceuticals (RCKT) rating was a maintained with a price target of $51.00 to $52.00. The current price Rocket Pharmaceuticals (RCKT) is trading at is $8.95, which is out of the analyst’s predicted range.